GlassScriptPhysician profile
Carla D Johnson
NPI 1578626412
$7,229.47
in general payments reported to CMS, 2019-2025
43 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,501 · 2022: $1,372 · 2023: $1,630 · 2024: $1,534 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,356.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $951.07 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $648.22 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $498.42 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $413.51 | 2022-2025 | |
| Lilly USA, LLC | $408.37 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Neurocrine Biosciences, INC. | $395.05 | 2022-2024 | Ingrezza, Ongentys |
| Pfizer INC. | $353.79 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $339.45 | 2021-2025 | |
| Amgen INC. | $295.35 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.24 | 2021-2025 | Jardiance, Ofev |
| E.R. Squibb & Sons, L.L.C. | $288.47 | 2021-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $260.73 | 2021-2024 | Capvaxive |
| Janssen Pharmaceuticals, INC | $240.84 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $202.68 | 2021-2024 | Airsupra, Breztri, Evusheld |
| Sumitomo Pharma America, INC. | $167.75 | 2023-2025 | Gemtesa, Aptiom |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $162.80 | 2021-2025 | |
| Astellas Pharma US INC | $139.47 | 2021-2024 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $101.99 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $91.30 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.26 | 2022-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.45 | 2023-2024 | Xifaxan |
| Ardelyx, INC. | $77.45 | 2025 | Ibsrela |
| Sunovion Pharmaceuticals INC. | $74.75 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.44 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $59.52 | 2025 | Rexulti |
| Corcept Therapeutics | $49.11 | 2024-2025 | Korlym |
| Teleflex LLC | $47.54 | 2024 | Urolift |
| Ironwood Pharmaceuticals, INC | $46.51 | 2021-2023 | Linzess |
| Shield Therapeutics INC | $45.50 | 2024 | |
| Paratek Pharmaceuticals, INC. | $39.76 | 2023 | Nuzyra |
| Eisai INC. | $37.09 | 2021 | |
| Phathom Pharmaceuticals, INC. | $35.79 | 2024-2025 | Voquezna |
| Nevro Corp. | $34.70 | 2021 | |
| Amarin Pharma, INC. | $28.55 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.09 | 2021 | |
| Abbott Laboratories | $26.99 | 2021-2022 | |
| Organogenesis INC. | $21.92 | 2025 | Puraply Wound Matrix |
| Exact Sciences Corporation | $19.36 | 2024 | Cologuard Collection Kit |
| Seqirus USA INC | $18.91 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Teva Pharmaceuticals USA, INC. | $17.36 | 2021 | |
| Genentech USA, INC. | $15.07 | 2025 | Ocrevus Zunovo |
| Arbor Pharmaceuticals, INC. | $13.13 | 2021 | |
| Corium, LLC | $11.72 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.